These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28755607)

  • 1. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.
    Vergote IB; Smith DC; Berger R; Kurzrock R; Vogelzang NJ; Sella A; Wheler J; Lee Y; Foster PG; Weitzman R; Buckanovich RJ
    Eur J Cancer; 2017 Sep; 83():229-236. PubMed ID: 28755607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
    Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
    Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
    Hellerstedt BA; Vogelzang NJ; Kluger HM; Yasenchak CA; Aftab DT; Ramies DA; Gordon MS; Lara P
    Clin Lung Cancer; 2019 Mar; 20(2):74-81.e1. PubMed ID: 30528315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
    Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
    Kelley RK; Verslype C; Cohn AL; Yang TS; Su WC; Burris H; Braiteh F; Vogelzang N; Spira A; Foster P; Lee Y; Van Cutsem E
    Ann Oncol; 2017 Mar; 28(3):528-534. PubMed ID: 28426123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
    Daud A; Kluger HM; Kurzrock R; Schimmoller F; Weitzman AL; Samuel TA; Moussa AH; Gordon MS; Shapiro GI
    Br J Cancer; 2017 Feb; 116(4):432-440. PubMed ID: 28103611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on "Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial." Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, SchoffskiSchöffski P, Scheffold C, Weitzman AL, Hussain M, University of Michigan, Ann Arbor, MI. J Clin Oncol 2013;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19.
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1848. PubMed ID: 24210087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
    Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
    J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
    Apolo AB; Nadal R; Tomita Y; Davarpanah NN; Cordes LM; Steinberg SM; Cao L; Parnes HL; Costello R; Merino MJ; Folio LR; Lindenberg L; Raffeld M; Lin J; Lee MJ; Lee S; Alarcon SV; Yuno A; Dawson NA; Allette K; Roy A; De Silva D; Lee MM; Sissung TM; Figg WD; Agarwal PK; Wright JJ; Ning YM; Gulley JL; Dahut WL; Bottaro DP; Trepel JB
    Lancet Oncol; 2020 Aug; 21(8):1099-1109. PubMed ID: 32645282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.
    Cabanillas ME; Brose MS; Holland J; Ferguson KC; Sherman SI
    Thyroid; 2014 Oct; 24(10):1508-14. PubMed ID: 25102375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
    Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
    J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabozantinib in progressive medullary thyroid cancer.
    Elisei R; Schlumberger MJ; Müller SP; Schöffski P; Brose MS; Shah MH; Licitra L; Jarzab B; Medvedev V; Kreissl MC; Niederle B; Cohen EE; Wirth LJ; Ali H; Hessel C; Yaron Y; Ball D; Nelkin B; Sherman SI
    J Clin Oncol; 2013 Oct; 31(29):3639-46. PubMed ID: 24002501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H
    Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
    Abou-Alfa GK; Meyer T; Cheng AL; El-Khoueiry AB; Rimassa L; Ryoo BY; Cicin I; Merle P; Chen Y; Park JW; Blanc JF; Bolondi L; Klümpen HJ; Chan SL; Zagonel V; Pressiani T; Ryu MH; Venook AP; Hessel C; Borgman-Hagey AE; Schwab G; Kelley RK
    N Engl J Med; 2018 Jul; 379(1):54-63. PubMed ID: 29972759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
    Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
    Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
    Wen PY; Drappatz J; de Groot J; Prados MD; Reardon DA; Schiff D; Chamberlain M; Mikkelsen T; Desjardins A; Holland J; Ping J; Weitzman R; Cloughesy TF
    Neuro Oncol; 2018 Jan; 20(2):249-258. PubMed ID: 29016998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
    Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
    J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
    Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
    Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.